** Shares of gene therapy company MeiraGTx Holdings plc MGTX.O up 13.6% at $7.76 premarket
** Co says early-stage study data for its experimental gene therapy, rAAV8.hRKp.AIPL1, showed safety, efficacy and meaningful responses for treatment of genetic eye condition called retinal dystrophy
** Says children who were blind at birth were treated with the gene therapy and showed visual acuity in eyes after four or more weeks in small study
** The therapy showed improved functional vision and evidence of protection against progressive retinal degeneration, without serious adverse effects
** Retinal dystrophy is caused due to genetic deficiency of type of protein called AIPL1, which leads severe impairment of sight from birth
** Co says study data is published in medical journal The Lancet
** MGTX stock has risen ~16% in last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。